Latest & greatest articles for Psoriasis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Psoriasis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Psoriasis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales. These patches normally appear on your elbows, knees, scalp and lower back, but can appear anywhere on your body. Most people are only affected with small patches. In some cases, the patches can be itchy or sore.

Top results for Psoriasis

1. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. Full Text available with Trip Pro

National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. To systematically review and provide information on the incidence of psoriasis and quantify global, regional, and country specific estimates of its prevalence.Systematic review and meta-analysis.Medline, Embase, Web of Science, SciELO, Korean Journal Databases, Russian Science Citation Index, WPRIM, SaudiMedLit, Informit, IndMed, and HERDIN were searched systematically from their inception (...) dates to October 2019.Studies were included if they reported on the incidence or prevalence of psoriasis in the general population. Incidence data were summarised descriptively, whereas bayesian hierarchical models were fitted to estimate the global, regional, and country specific prevalence of psoriasis.41 164 records were identified and 168 studies met the inclusion criteria. In adults, the incidence of psoriasis varied from 30.3 per 100 000 person years (95% confidence interval 26.6 to 34.1

2020 BMJ

2. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (Abstract)

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. Plaque (...) psoriasis is associated with a number of comorbidities including psoriatic arthritis, cardiometabolic diseases, and depression. For patients with mild psoriasis, topical agents remain the mainstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibitors, and keratolytics. The American Academy of Dermatology-National Psoriasis Foundation guidelines recommend biologics as an option for first-line treatment of moderate to severe plaque psoriasis because

2020 JAMA

3. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis in pediatric patients Full Text available with Trip Pro

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis in pediatric patients Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients - Journal of the American Academy of Dermatology Email/Username: Password: Remember me Search JAAD & JAAD Case Reports Search Terms Search within Search Volume 82, Issue 1, Pages 161–201 To read this article in full, please review your options (...) for gaining access at the bottom of the page. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients x Alan Menter Affiliations Baylor University Medical Center, Dallas, Texas , MD (Co-Chair) a , x Kelly M. Cordoro Affiliations University of California, San Francisco School of Medicine, Department of Dermatology, San Francisco, California , MD b , x Dawn M.R. Davis Affiliations Mayo Clinic, Rochester

2020 American Academy of Dermatology

4. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis Full Text available with Trip Pro

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.We assembled a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018. Exposure was dispensation

2019 EvidenceUpdates

5. Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Risankizumab (Plaque-Psoriasis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 August 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-41 (...) Risankizumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-41 Version 1.0 Risankizumab (plaque psoriasis) 29 August 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Risankizumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 2 May

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Certolizumab pegol (Cimzia) - Psoriasis, moderate to severe plaque

Certolizumab pegol (Cimzia) - Psoriasis, moderate to severe plaque certolizumab pegol | CADTH.ca Find the information you need certolizumab pegol certolizumab pegol Last Updated: October 3, 2019 Result type: Reports Project Number: SR0587-000 Product Line: Generic Name: certolizumab pegol Brand Name: Cimzia Manufacturer: UCB Canada Inc. Indications: Psoriasis, moderate to severe plaque Manufacturer Requested Reimbursement Criteria 1 : For the treatment of adult patients with moderate to severe (...) plaque psoriasis who are candidates for systemic therapy. Submission Type: New Indication Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable. Key Milestones 2 Call for patient input posted October 15, 2018 Patient group input closed December 03, 2018 Clarification: - Patient

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

7. Risankizumab (Skyrizi) - patients with moderate to severe plaque psoriasis

Risankizumab (Skyrizi) - patients with moderate to severe plaque psoriasis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2019 Health Canada - Drug and Health Product Register

8. Risankizumab (Skyrizi) - plaque psoriasis

Risankizumab (Skyrizi) - plaque psoriasis 1 Published 07 October 2019 1 SMC2196 risankizumab 75mg solution for injection in pre-filled syringe (Skyrizi®) AbbVie Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission risankizumab (Skyrizi ® ) is accepted for restricted (...) use within NHSScotland. Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments. Risankizumab was superior to placebo, a tumour necrosis factor antagonist, and an interleukin 12/23 antagonist in improving

2019 Scottish Medicines Consortium

9. Risankizumab (Skyrizi) - Psoriasis

Risankizumab (Skyrizi) - Psoriasis Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2019 Health Canada - drugs and medical devices

10. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Full Text available with Trip Pro

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities - Journal of the American Academy of Dermatology Email/Username: Password: Remember me Search JAAD & JAAD Case Reports Search Terms Search within Search Access provided by Volume 80, Issue 4, Pages 1073–1113 Joint AAD-NPF guidelines of care (...) for the management and treatment of psoriasis with awareness and attention to comorbidities x Craig A. Elmets Affiliations University of Alabama, Birmingham, Alabama , MD ((Co-Chair)) a , x Craig L. Leonardi Affiliations Central Dermatology, St. Louis, Missouri , MD b , x Dawn M.R. Davis Affiliations Mayo Clinic, Rochester, Minnesota , MD c , x Joel M. Gelfand Affiliations University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania , MD, MSCE d , x Jason Lichten Affiliations National

2019 American Academy of Dermatology

11. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. (Abstract)

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor, guselkumab, versus an IL-17A inhibitor, secukinumab. The primary objective of this study was to show superiority of clinical response at week 48 for guselkumab versus secukinumab.In (...) this phase 3, multicentre, double-blind, randomised, comparator-controlled trial at 142 outpatient clinical sites in nine countries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and the USA), eligible patients were aged 18 years or older, had moderate-to-severe plaque-type psoriasis, and were candidates for phototherapy or systemic therapy. Eligible patients were randomly assigned with permuted block randomisation using an interactive web response system to receive either

2019 Lancet Controlled trial quality: predicted high

12. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. (Abstract)

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis.IMMvent was a phase 3, randomised (...) , double-blind, active-comparator-controlled trial completed at 66 clinics in 11 countries. Eligible patients were aged 18 years or older with moderate-to-severe chronic plaque psoriasis. Patients were randomly assigned 1:1 using interactive response technology to receive 150 mg risankizumab subcutaneously at weeks 0 and 4 or 80 mg adalimumab subcutaneously at randomisation, then 40 mg at weeks 1, 3, 5, and every other week thereafter during a 16-week double-blind treatment period (part A). For weeks

2019 Lancet Controlled trial quality: predicted high

13. Tildrakizumab (Ilumetri) - treatment of adults with moderate to severe plaque psoriasis

Tildrakizumab (Ilumetri) - treatment of adults with moderate to severe plaque psoriasis Published 12 August 2019 1 SMC2167 tildrakizumab 100mg solution for injection in pre- filled syringe (Ilumetri®) Almirall Limited 5 July 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) tildrakizumab (Ilumetri ® ) is accepted for restricted use within NHSScotland. Indication under review: The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. SMC restriction: for use in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments. Tildrakizumab was superior to placebo in improving the signs and symptoms

2019 Scottish Medicines Consortium

14. Risankizumab for treating moderate to severe plaque psoriasis

Risankizumab for treating moderate to severe plaque psoriasis Risankizumab for treating moder Risankizumab for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 21 August 2019 www.nice.org.uk/guidance/ta596 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Risankizumab for treating moderate to severe plaque psoriasis (TA596) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 13Contents Contents 1 Recommendations 4 2 Information about

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

15. Lifestyle changes for treating psoriasis. (Abstract)

Lifestyle changes for treating psoriasis. Psoriasis is an inflammatory skin disease that presents with itching, red, scaling plaques; its worsening has been associated with obesity, drinking, smoking, lack of sleep, and a sedentary lifestyle. Lifestyle changes may improve psoriasis.To assess the effects of lifestyle changes for psoriasis, including weight reduction, alcohol abstinence, smoking cessation, dietary modification, exercise, and other lifestyle change interventions.We searched (...) or in combination) for treating psoriasis in people diagnosed by a healthcare professional. Treatment had to be given for at least 12 weeks. Eligible comparisons were no lifestyle changes or another active intervention.We used standard methodological procedures expected by Cochrane. The primary outcome measures were 'Severity of psoriasis' and 'Adherence to the intervention'. Secondary outcomes were 'Quality of life', 'Time to relapse', and 'Reduction in comorbidities'. We used GRADE to assess the quality

2019 Cochrane Controlled trial quality: predicted high

16. Risankizumab rzaa (Skyrizi) - To treat moderate-to-severe plaque psoriasis

Risankizumab rzaa (Skyrizi) - To treat moderate-to-severe plaque psoriasis Drug Approval Package: Skyrizi U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Skyrizi Company: AbbVie, Inc. Application Number: 761105 Approval Date: 04/23/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2019 FDA - Drug Approval Package

17. WITHDRAWN: Interventions for guttate psoriasis. (Abstract)

WITHDRAWN: Interventions for guttate psoriasis. Guttate psoriasis is a distinctive acute form of psoriasis which characteristically occurs in children and young adults. Very little specific evidence-based guidance is available in standard texts to help make rational decisions about treatment options.To assess the effectiveness of treatments for guttate psoriasis.We searched the Cochrane Clinical Trials Register (Cochrane Library, Issue 3, 1999), Medline (1966- September 1999), Embase (1988 (...) -September 1999), Salford Database of Psoriasis Trials (to November 1999) and European Dermato-Epidemiology Network (EDEN) Psoriasis Trials Database (to November 1999) for terms GUTTATE and PSORIASIS. We also searched 100 unselected RCTs of psoriasis therapy and all 112 RCTs of phototherapy for psoriasis in the Salford Database of Psoriasis Trials for separate stratification for guttate psoriasis.Randomised trials in which patients with acute guttate psoriasis were randomised to different treatments

2019 Cochrane

18. Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. (Abstract)

Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. Guttate psoriasis displays distinctive epidemiological and clinical features, making it a separate entity within the heterogeneous group of cutaneous psoriasis types. It is associated with genetic, immune, and environmental factors (such as stress and infections) and usually arises in younger age groups (including children, teenagers, and young adults). There is currently no cure (...) for psoriasis, but various treatments can help to relieve the symptoms and signs. The objectives of treatment when managing an acute flare of guttate psoriasis are to reduce time to clearance and induction of long-term remission after resolution. This is an update of a Cochrane Review first published in 2000; since then, new treatments have expanded the therapeutic spectrum of systemic treatments used for psoriasis.To assess the effects of non-antistreptococcal interventions for acute guttate psoriasis

2019 Cochrane

19. Guselkumab (plaque psoriasis) - Addendum to Commission A17-60

Guselkumab (plaque psoriasis) - Addendum to Commission A17-60 1 Translation of addendum A18-24 Guselkumab (Plaque-Psoriasis) – Addendum zum Auftrag A17-60 (Version 1.0; Status: 27 April 2018). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 27 April 2018 1.0 Commission: A18-24 Version: Status: IQWiG Reports – Commission No. A18-24 Guselkumab (plaque (...) psoriasis) – Addendum to Commission A17-60 1 Addendum A18-24 Version 1.0 Guselkumab – Addendum to Commission A17-60 27 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Guselkumab (plaque psoriasis) – Addendum to Commission A17-60 Commissioning agency: Federal Joint Committee Commission awarded on: 9 April 2018 Internal Commission No.: A18-24 Address of publisher: Institut für Qualität und

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

20. Certolizumab pegol (Cimzia) - the treatment of moderate to severe plaque psoriasis

Certolizumab pegol (Cimzia) - the treatment of moderate to severe plaque psoriasis 1 Published 08 April 2019 1 SMC2132 certolizumab pegol 200mg solution for injection in pre-filled syringe and pen (Cimzia®) UCB Pharma Ltd 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) certolizumab pegol (Cimzia ® ) is accepted for restricted use within NHSScotland. Indication under review: the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra- indication to these treatments. Certolizumab pegol has shown a similar reduction in the signs and symptoms of psoriasis

2019 Scottish Medicines Consortium